新股消息 | 景泽生物二次递表港交所 共有八个候选药物

Core Viewpoint - Jingze Biopharmaceutical (Hefei) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC and Guoyuan International as joint sponsors. The company previously filed an application on June 27, 2025 [1]. Company Overview - The company, established in 2014, focuses on biopharmaceuticals in the fields of assisted reproduction and ophthalmology. It has two core products: JZB30, a recombinant human follicle-stimulating hormone (rhFSH) injection for assisted reproduction, and JZB05, an anti-VEGF intravitreal injection candidate for treating retinal neovascular diseases [4][5]. Product Pipeline - As of December 21, 2025, the company has eight drug candidates, with three in late-stage development, including one that has received NDA approval, one that has submitted an NDA, and one in Phase 3 clinical trials. The product portfolio addresses clinical indications in assisted reproduction and ophthalmology [5]. Key Products - JZB30 is the company's first commercialized product in assisted reproduction, targeting the global ovulation induction market. It has completed Phase 1 and Phase 3 clinical studies and received NDA approval in April 2025 [6][7]. - JZB05 is expected to be the first commercialized product in the ophthalmology field, targeting diseases like wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). It has completed Phase 1 clinical studies and entered Phase 3 trials in September 2023, with NDA submission expected in the second half of 2026 [7]. - JZB33, another product, is a recombinant human follicle-stimulating hormone injection that improves patient compliance through a user-friendly delivery system. It has received approval for a simplified clinical study and is expected to submit an NDA in June 2025 [8]. Financial Information - The company's other income for the fiscal years ending June 30, 2023, 2024, and 2025 was approximately RMB 9.8 million, RMB 12.4 million, and RMB 0.83 million, respectively [10]. - The company reported total losses of approximately RMB 246.2 million, RMB 242.7 million, and RMB 128.1 million for the same periods [11]. - Research and development expenses were approximately RMB 122.0 million, RMB 133.0 million, and RMB 50.8 million for the respective fiscal years [12]. Industry Overview - The global biopharmaceutical market is projected to grow from USD 286.4 billion in 2019 to USD 441.9 billion by 2024, with a compound annual growth rate (CAGR) of 9.1%. It is expected to reach USD 828.6 billion from 2025 to 2030, with a CAGR of 11.0% [16]. - The Chinese biopharmaceutical market is expected to grow from RMB 312 billion in 2019 to RMB 493 billion by 2024, with a CAGR of 9.6%, and further to RMB 1,021 billion from 2025 to 2030, with a CAGR of 13.1% [16]. - The market for assisted reproductive drugs in China is projected to grow from RMB 4.2 billion in 2019 to RMB 5.7 billion by 2024, with a CAGR of 6.0%, and further to RMB 11.9 billion from 2025 to 2030, with a CAGR of 13.5% [19]. - The ophthalmic drug market in China is expected to grow from RMB 19.4 billion in 2019 to RMB 29.5 billion by 2024, with a CAGR of 8.7%, and further to RMB 53.7 billion by 2030, with a CAGR of 11.0% from 2025 to 2030 [22].